(secondQuint)CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis.

 Patients aged 18 to 75 years with mucocutaneous candidiasis (esophageal, oropharyngeal, or vulvovaginal) who are refractory or intolerant to standard non-intravenous therapies will be enrolled.

 Patients will initially be treated in a short-term dose titration period, where the dose may be increased in patients that do not respond clinically.

 Patients who do not respond clinically to the highest dose of drug will discontinue the protocol.

 Patients that respond to treatment and tolerate the study medication will be eligible to enter a long-term extension (up to 6-months).

.

 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis@highlight

This is an open-label, dose-titration trial to study the efficacy, safety, and pharmacokinetics of oral cochleate amphotericin B (CAMB) in the treatment of mucocutaneous candidiasis infections in patients who are refractory or intolerant to standard non intravenous therapies.

